WO2012111878A1 - Composition pharmaceutique contenant la protéine hybride de superoxyde dismutase, destinée à prévenir ou traiter les maladies des yeux - Google Patents

Composition pharmaceutique contenant la protéine hybride de superoxyde dismutase, destinée à prévenir ou traiter les maladies des yeux Download PDF

Info

Publication number
WO2012111878A1
WO2012111878A1 PCT/KR2011/002394 KR2011002394W WO2012111878A1 WO 2012111878 A1 WO2012111878 A1 WO 2012111878A1 KR 2011002394 W KR2011002394 W KR 2011002394W WO 2012111878 A1 WO2012111878 A1 WO 2012111878A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
eye
protein
superoxide dismutase
seq
Prior art date
Application number
PCT/KR2011/002394
Other languages
English (en)
Korean (ko)
Inventor
최수영
김대원
이성호
박진서
음원식
Original Assignee
한림대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한림대학교 산학협력단 filed Critical 한림대학교 산학협력단
Publication of WO2012111878A1 publication Critical patent/WO2012111878A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Definitions

  • the present invention relates to a dry eye treatment agent, and more particularly to a pharmaceutical composition for treating dry eye syndrome containing a superoxide dismutase fusion protein that can penetrate into the eye tissue as an active ingredient.
  • Corneal transplantation is a surgical procedure that restores vision by replacing the cloudy cornea of a patient with vision loss due to corneal disease with a donated clean cornea. Corneal transplantation is the most frequently performed transplantation worldwide due to the development of corneal preservation methods, the development of surgical techniques and instruments, and the treatment of rejection reactions. The eyeball can be transplanted even after cardiopulmonary arrest. This is the only activated organ transplantation in Korea, where brain death is not legally recognized with a high success rate compared to other organs. According to the National Organ Transplantation Management Center in Korea, corneal transplantation is increasing every year, and the number of corneal transplants in 2007 was 405, and in the United States, the number exceeds 40,000 from 1990 to 2007.
  • Corneal graft rejection accounts for the majority of corneal graft failures. Although steroids have been used mainly to reduce rejection in corneal transplantation, complications such as increased intraocular pressure, delayed wound healing, and cataracts can occur if steroids are used for a long time, and high doses do not prevent rejection. Recently, attempts have been made to reduce rejection by using immunosuppressants rather than steroids. In the high-risk corneal graft group, the group treated with cyclosporine A, an immunosuppressive agent, showed higher rejection than the steroid-only group. Was reported. In experimental animal models, there was less postoperative invasion of inflammatory cells after surgery than in the FK506 (Tacrolimus) group.
  • FK506 Tropus
  • cyclosporin A cyclosporin A in organ transplant patients is excellent in immunosuppressive effects, but side effects of drugs such as nephrotoxicity, hypertension, metabolic disorders, and risk of diabetes have been pointed out as problems of use.
  • Autoimmune disease is an autoimmune disease that occurs when the body's defense mechanisms, ie when the immune system starts to damage it against its body tissues, and patients are still on the rise.
  • Autoimmune disease is a disease caused by excessive or inadequate control of the autoimmune response by inducing an inappropriate immune response as the environment of the body's cytokine (signaling substance that controls and stimulates the body's defense system) against viruses or bacteria is induced.
  • the exact cause of the disease is not known and may be caused by environmental, genetic, or immunological factors.
  • autoimmune eye diseases include uveitis, Behcet's disease, and keratoconjunctivitis, and dry eye is also regarded as an inflammatory disease due to an abnormal immune response, and dryness is also regarded as an autoimmune disease. Most autoimmune diseases use steroids or immunosuppressants in recent years.
  • One of the representative autoimmune eye diseases is uveitis.
  • the uvea consists of the iris, ciliary and choroid.
  • the uvea is rich in blood vessels and connective tissue.
  • Inflammation of the uvea is called uveitis, and the cause of the disease is unclear until now, but the cause is considered syphilis and tuberculosis.
  • the cause of uveitis is currently looking at the immune system abnormalities. Inflammation at the uveal may be caused by bacteria or viruses, but the immune response is a lot of inflammation is classified as an autoimmune disease.
  • Uveitis has been treated with topical or systemic steroids. However, topical treatments such as eye drops or systemic steroid treatments require high doses when the drug does not reach the uveal tissue, which often results in serious side effects.
  • immunosuppressive drugs are used in patients who do not respond to steroid treatment or patients who cannot tolerate the severe side effects of systemic steroids, which have been discontinued due to side effects such as bone marrow suppression, hemorrhagic cystitis and kidney damage. These patients often lead to blindness. Therefore, it is urgent to develop eye drops for eye diseases with good eye penetration and few side effects.
  • Dry eye syndrome is a syndrome in which tear film is insufficient or the tear film is excessively evaporated and the tear film becomes unstable, resulting in various symptoms such as foreign body or stinging. Dry eye syndrome is associated with decreased tear secretion, disease of the eyeballs and eye appendages, such as eyelid abnormalities or inflammation, and skin diseases (Stevenson-Johnson syndrome, pemphigoid), and systemic diseases ( Vitamin A deficiency, Sjogren's syndrome) (Ophthalmology, 7th edition, Sculpture, Yoon Dong-ho. According to a recent survey by Chung-Ang University Hospital, 75% of Korean adults suffer from dry eye, and one out of three is a serious patient with inflammation of the cornea.
  • Treatment for dry eye syndrome focused on maintaining a certain amount of tears by conservative methods such as supplementing artificial eye drops or temporarily or permanently preventing tears, but recently dry eye syndrome has been newly recognized as an inflammatory disease.
  • Anti-inflammatory treatments for dry eye syndrome have been actively attempted, and the effects have been reported for severe dry eye patients.
  • Inflammation of the ocular surface became a concern in the treatment of dry eye syndrome, as evidenced by increased T-lymphocytes and high levels of cytokines and various inflammatory mediators.
  • One such drug is cyclosporin A 0.05% eye drop (Restasis).
  • side effects occur in dry eye patients, and the most common adverse reaction is burning sensation in the eye (a sensation of burning when the drug touches the skin or tongue) and conjunctival hyperemia in 1-5% of patients.
  • Secretions, seborrhea, eye pain, foreign body sensation, pruritus, pain, visual acuity (often blurred vision) have been reported. Therefore, there is a need for the development of new inflammatory and immunosuppressive agents with fewer side effects.
  • Immunosuppressants refer to a variety of substances used by the host to reduce or block the ability to make antibodies (humoral immunity) or cellular immune responses, and mainly include selective immunosuppression, such as autoimmune diseases and fetal fibrosis; Used for therapeutic purposes to prevent rejection after organ transplantation.
  • immunosuppressants have side effects such as anemia, leukopenia, thrombocytopenia, and hair loss, and are therefore limited in use.
  • Cytotoxic agents with low cytotoxicity have been developed from secondary metabolites of bacteria and fungi, and cyclosporin A and FK506 (Tacrolimus), which are currently the most widely used in organ transplant patients, are typically used, but side effects are not completely reduced.
  • Ophthalmic disease therapies need to be changed from systemic to topical use and new drug development to reduce side effects of existing drugs.
  • the most commonly used immunosuppressive agents, cyclosporin and FK506 are used systemically. Both drugs can cause damage to the kidneys and nervous system, which makes it difficult to use them widely.
  • Development studies into eye drop formulations are actively underway. There has been a published paper showing that the use of FK506 in eye drops to suppress rejection after corneal transplantation has been shown to have an excellent effect on delaying rejection. All have been reported to have had a good effect.
  • eye drops containing cyclosporine in patients with dry eye syndrome were reported to have increased tear secretion, especially in dry eye associated with systemic diseases.
  • corneas are well penetrated by drugs having amphoteric and hydrophilic amphoteric properties. Therefore, in order to increase the permeability of the drug that does not penetrate the cornea well, the amount to be used in excess of the amount originally administered may result in side effects.
  • Patent No. 472938 relates to a transport domain-target protein-transport domain fusion protein and its use for improved cell penetration efficiency, wherein protein transport domains such as HIV-1 Tat peptide, oligolysine, oligoarginine, Disclosed is a fusion protein covalently attached to the terminal and / or C-terminus to enhance cell permeability.
  • Patent No. 493662 discloses a technique in which oligolysine as a protein transport domain is covalently bonded to the N-terminus and / or C-terminus of a protein to improve cell permeability.
  • HIV-a Tat peptide oligolysine, oligoarginine, oligos (lysine, arginine) and PEP-1 peptides enhance the cellular permeability of proteins.
  • Patent Publication No. 2002-10445 discloses a Tat-superoxide dismutase fusion protein and discloses the use of therapeutic agents such as glomerulonephritis and vasculitis.
  • an object of the present invention is to provide an ocular disease protein therapeutic agent for eye drops.
  • the present inventors studied to develop a protein agent, which is an immune response suppressing drug, into a formulation for enhancing the ocular penetration ability, and completed the present invention by identifying an ophthalmic disease therapeutic effect of an ophthalmic protein preparation.
  • the inventors of the present invention found that one of the protein transport domains, preferably PEP-1 peptides, derivatives thereof, HIV-1 Tat peptides, derivatives thereof, oligolysine, oligoarginine, oligo (lysine + arginine), which carries proteins in the cell in nature. More than one species were fused to the N- and / or C-terminus of the external protein human superoxide dismutase (hereinafter referred to as "SOD”), which was overexpressed in E. coli and metal chelating affinity chromatography Purification was easy and convenient by chromatography. In addition, it was confirmed through experiments that the purified fusion protein effectively improves eye diseases including dry eye. The present invention has raised the possibility of applying superoxide dismutase fusion proteins as protein therapeutics for ophthalmic diseases.
  • SOD human superoxide dismutase
  • the present invention provides a superoxide dismutase fusion in which protein transport domains such as PEP-1 and Tat are covalently bonded to at least one of the N-terminus and C-terminus of the superoxide dismutase.
  • a pharmaceutical composition for the treatment of ophthalmic diseases containing a protein (combined with "SOD fusion protein” hereinafter).
  • the invention contains a superoxide dismutase fusion protein, and provides a pharmaceutical composition for the treatment of eye diseases such as dry eye.
  • the superoxide dismutase fusion proteins of the invention are useful for the treatment of eye diseases, typically for the treatment of dry eye syndrome.
  • ophthalmic disease refers to Stevenson-Johnson syndrome, Sjogren's syndrome, dry eye syndrome, trauma, eye trauma by eye surgery (eye surgery means any surgery to incision the eye, typically cataract surgery, Glaucoma surgery, retinal surgery, LASIK surgery, Lasek surgery, etc.), infectious / non-infective uveitis, immunorejection after corneal transplantation, or corneal epithelial disorder due to exogenous disease caused by wearing hard contact lenses.
  • the ophthalmic disease is not necessarily limited thereto, and preferably includes dry eye syndrome.
  • dry eye refers to a syndrome in which tear generation is insufficient or tears of the tear film are excessively evaporated, resulting in unstable tear film and various symptoms such as foreign body or stinging. More specifically, “dry eye syndrome” refers to Stevenson-Johnson syndrome or pemphigoid, which is a condition that is accompanied by decreased tear secretion or disease of the eyeballs and eye appendages, such as eyelid abnormalities, inflammation, or skin diseases. Vitamin A deficiency and Sjogren's syndrome, which is associated with the disease, impairs the surface of the eyeballs in the gaps of the exposed eyelids and causes irritation such as discomfort, foreign bodies, and dryness, and inflammation of the eye surface when the corneal damage is severe. Say disease. As the lesion progresses, congestion may be seen. Complications may include mild visual impairment at first, followed by corneal ulcers, corneal perforation, and secondary bacterial infections, and severe corneal scarring and angiogenesis. .
  • the superoxide dismutase fusion protein is basically an immunoassay method (eg, a radioimmunoassay method, a radioimmunoprecipitation method, an enzyme-linked immunity) using genetic recombination of a protein, an antigen-antibody reaction.
  • an immunoassay method eg, a radioimmunoassay method, a radioimmunoprecipitation method, an enzyme-linked immunity
  • ELISA Adsorption method
  • dot blot analysis e.g., western blot, inhibition or competition assay and sandswitch analysis
  • Enzyme Immunoassay ET Maggio, ed., CRC Press, Boca Raton, Florida, 1980; and Gaastra, W.
  • Quantitative or qualitative analysis was performed according to an enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology , Vol. 1, Walker, JM ed., Humana Press, NJ, 1984), and molecular
  • Efficacy verification for the ophthalmic disease represented by the superoxide dismutase fusion protein in the present invention can be carried out using a number of related papers and known dry eye animal models.
  • the inventors used a dry blowing induced lett eye dry model as a short-term dry eye syndrome model.
  • Surgical epithelial damage of 0.4 mm2 was applied to the median portion of the cornea using a surgical knife, and then dry eye was caused by exposure to a dry blower with a humidity of 25-30% and 2.4 m / sec.
  • the tear secretion was measured, and corneal damage rate was measured using a fluorescent dye.
  • the conjunctival eye and bleeding conjunctiva were extracted and examined histopathologically.
  • Apoptosis of corneal epithelial cells was evaluated immunohistochemically using PARP ⁇ poly (ADP-ribose) polymerase ⁇ .
  • the efficacy of the superoxide dismutase fusion protein on dry eye syndrome was compared to the validated 0.1% sodium hyaluronate (see Johnson et al. 2006, 2008) eye groups.
  • a botulinum toxin-A induced mouse dry eye model was used as another dry eye model. 20 mU of BTX-A is injected into the lacrimal gland into the transconjunctival root to inject BTX-A into the tear-secreting portion of the lacrimal gland orbital lobe, causing dry eye I was. The corneal damage rate was measured using fluorescent dyes for dry eye efficacy test, and the conjunctiva attached eye and bleeding conjunctiva were removed and histopathologically observed.
  • Superoxide dismutase fusion protein as a novel dry eye treatment substance was calculated as 0.01mg / kg corresponding to 6 times of the effective dose 0.1% solution for the single dose intravenous toxicity test, and 500mg corresponding to 500 times. Toxicity experiment was performed by setting / kg as high dose group and 2.5mg / kg as low dose group.
  • the superoxide dismutase fusion protein according to the present invention significantly increased tear secretion in the dry eye animal model, increased the thickness of conjunctival epithelium thinned due to inflammation, and increased the number of mucus producing cells.
  • the superoxide dismutase fusion protein according to the present invention reduced apoptosis during eye injury and decreased corneal damage.
  • the present invention relates to an eye drop composition for preventing and treating ophthalmic diseases comprising a fusion protein having a protein transport domain covalently attached to at least one of the N-terminus and the C-terminus of a superoxide dismutase.
  • the protein transport domain In the present invention, the protein transport domain
  • a hydrophobic domain consisting of 15-30 amino acids, comprising at least five tryptophan, a hydrophilic domain containing at least four lysines, and a spacer separating the two domains ( protein transport domain, consisting of
  • a protein transport domain consisting of 6-12 amino acid residues and comprising at least 3/4 of arginine or lysine residues
  • oligolysine protein transport domain consisting of 6 to 12 lysines
  • an oligoarginine protein transport domain consisting of 6 to 12 arginine and
  • oligo (lysine, arginine) protein transport domains consisting of 6 to 12 lysine or arginine and derivatives of a) to e).
  • the present invention is characterized in that the fusion protein is one selected from SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14.
  • the ophthalmic disease is characterized by corneal conjunctival epithelial disorder caused by Stevenson-Johnson syndrome, Sjogren's syndrome, dry eye syndrome, or an exogenous disease caused by wearing trauma or hard contact lenses.
  • compositions containing a superoxide dismutase fusion protein as an active ingredient can be formulated into eye drops by conventional methods in combination with a carrier that is conventionally acceptable in the pharmaceutical art.
  • the eye drop composition is preferably an isotonic aqueous solution or suspension, and the composition mentioned is sterile and / or contains an adjuvant such as a preservative, stabilizer, wetting agent or salt / or buffer for osmotic pressure control. In addition, they may contain other therapeutically valuable substances.
  • eye drop compositions have been known to moisturize and lubricate anionic polymers such as hyaluronic acid and carboxymethylcellulose or their pharmaceutically acceptable salts in eye drops, and include, in addition to these components, pharmaceutically acceptable carriers.
  • pharmaceutically acceptable carriers include isotonic agents, buffers, stabilizers, pH adjusting agents and solvents. Isotonic agents play a role in controlling the isotonicity of eye drops, and typically, sodium chloride or potassium chloride may be selected.
  • the buffer performs the function of adjusting the acidity or alkalinity of the eye drops. Buffers usually used in the preparation of eye drops include aminocapronic acid, sodium dihydrogen phosphate and sodium dihydrogen phosphate.
  • Stabilizers play a role of stabilizing eye drops, and it is usually possible to use sodium edetate and / or sodium perborate as stabilizers.
  • pH adjusters adjust the pH of the eye drop composition, such as hydrochloric acid and / or sodium hydroxide. It is preferable to use sterile purified water or distilled water for injection as a solvent.
  • the eye drop according to the present invention is preferably a liquid formulation. A preservative, a preservative, etc. can be added to the said eye drop composition as needed.
  • the recommended amount of the eye drop composition and the number of times of use according to the present invention can be appropriately increased or decreased depending on the symptoms, once or three times a day, 5 to 6 times a day. Dosage levels for a particular patient may vary depending on the patient's weight, age, sex, health status, time of administration, frequency of administration, severity of the disease, and the like.
  • Intracellular delivery of a superoxide dismutase protein molecule consists of 15-30 amino acids in superoxide dismutase, a non-hydrophobic domain comprising five or more tryptophans, four lysines
  • the target protein is a cell permeable transport domain including Pep-1 or a HIV Tat cell permeable domain, in which a transport domain including a hydrophilic domain including a plurality of the above and a spacer separating the two domains is covalently bonded. This is accomplished by constructing a fusion protein in a covalently bonded form with the N-terminus and / or C-terminus of the superoxide dismutase.
  • An example of the transport domain of the present invention includes a PEP-1 peptide consisting of 21 amino acids and an amino acid sequence such as SEQ ID NO: 1, and an HIV Tat 49 to 57 peptide consisting of an amino acid sequence such as SEQ ID NO: 2.
  • the protein transport domain of the present invention is not limited only to the PEP-1 peptide of SEQ ID NO: 1, the HIV Tat 49-57 residue peptide of SEQ ID NO: 2, and lacks a partial substitution, addition or addition of the amino acid sequence of PEP-1 or HIV Tat.
  • a protein transport domain consisting of a non-hydrophobic domain, a hydrophilic domain containing four or more lysines, and a spacer separating the two domains, and the same and similar amino acid substitutions.
  • the present invention relates to an eye drop composition for treating ophthalmic diseases comprising a superoxide dismutase fusion protein covalently bonded with the above protein transport domain.
  • Superoxide dismutase fusion protein includes a protein transport domain and a superoxide dismutase, and is a genetic fusion of a protein transport domain with a cargo molecule (ie, superoxide dismutase in the present invention). Or covalent complexes formed by chemical bonds.
  • SOD fusion protein was used interchangeably.
  • Tat-SOD refers to a Tat protein transport domain coupled to the N-terminus of SOD in a superoxide dismutase fusion protein.
  • the "genetic fusion” means a linear, covalent linkage formed through the genetic expression of the DNA sequence encoding the protein.
  • Target cell also means a cell to which a cargo molecule is delivered by a transport domain, i.e., a target cell is a cell in the body, i. It is meant to include the microorganisms found.
  • target cells are meant to include extracellular cells, ie cultured animal cells, human cells or microorganisms. Specifically, in the present specification, the target cell refers to an eye cell.
  • protein transport domain refers to a covalent bond with a cargo molecule (target protein) peptide or protein, so that the peptide or protein can be introduced into a cell without the need for a separate receptor, carrier, or energy.
  • a cargo molecule target protein
  • PEP-1 peptide SEQ ID NO: 1
  • target protein refers to a molecule that is covalently bound to a PEP-1 protein transport domain and introduced into a cell to exhibit activity. It is synonymous with "cargo molecule”.
  • the protein transport domain is composed of 15 to 30 amino acids, a non-hydrophilic domain including 5 or more tryptophan, a hydrophilic domain including a large number of lysine and a protein transport domain consisting of a spacer separating the two domains, A transport domain consisting of 6 to 12 amino acid residues and containing at least 3/4 of an arginine or lysine residue, an oligolysine transport domain consisting of 6 to 12 lysines, an oligoarginine transport domain consisting of 6 to 12 arginines, or 6 And oligo (lysine, arginine) transport domains composed of from twelve lysine or arginine.
  • the target protein (cargo molecule) is superoxide dismutase.
  • the protein transport domain and the target protein may be substituted with other amino acid (s) of similar polarity in which one or more amino acids in the sequence are functionally equivalent in response to a silent change.
  • Amino acid substitutions in the sequence may be selected from other members of the class to which the amino acid belongs.
  • hydrophobic amino acid classifications include alanine, valine, leucine, isoleucine, phenylalanine, valine, tryptophan, proline and methionine.
  • Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine.
  • Positive basic amino acids include arginine, lysine and histidine.
  • Negatively charged acidic amino acids include aspartic acid and glutamic acid.
  • fragments or derivatives thereof having the same or similar biological activity within a range of homology between the fusion protein and the amino acid sequence of the present invention, such as 85-100%, are also included in the scope of the present invention.
  • the present invention is characterized in that the cell introducing superoxide dismutase fusion protein has an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 or SEQ ID NO: 14.
  • the present invention is characterized in that the protein transducing domain (PTD) is covalently bonded to one or both sides of the carboxy terminus and amino terminus of the superoxide dismutase.
  • PTD protein transducing domain
  • the present invention also relates to an eye drop composition for treating ophthalmic diseases comprising the cell-transducing superoxide dismutase fusion protein as an active ingredient.
  • the present invention also relates to an eye drop composition for treating ophthalmic diseases comprising the cell-introduced superoxide dismutase fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
  • the superoxide dismutase fusion protein according to the present invention significantly increased tear secretion in dry eye animal models.
  • the superoxide dismutase fusion protein according to the present invention increased the thickness of conjunctival epithelium thinned due to inflammation and increased the number of mucus producing cells.
  • the superoxide dismutase fusion protein according to the present invention reduced apoptosis during ocular injury, decreased corneal damage, and did not find any abnormality as a result of conducting toxicological experiments in vivo.
  • FIG. 1 is a diagram showing a cumulative test using 1 ⁇ 15 mm cobalt chloride paper and showing changes in tear secretion before and after dry blowing.
  • B represents before dry blowing
  • A represents after dry blowing.
  • the two controls were intact, that is, the group that did not perform dry blowing and the negative eye group that caused dry eye and did not receive the drug.
  • the drug control group is a control group to which hyaluronic acid is added
  • the test group is a group treated with the superoxide dismutase fusion protein of the present invention. Each drug was administered 5 ⁇ l per eye once every hour for 5 hours.
  • FIG. 2 is a histopathological picture of the effect of superoxide dismutase fusion protein drug on the conjunctival epithelial thickness and the number of mucus producing cells in a dry blowing-induced dry eye model using PAS staining.
  • A is a normal control group
  • B is a dry blowing induced negative control group
  • C is a drug control group administered hyaluronic acid
  • D is a test group administered a superoxide dismutase fusion protein.
  • Each drug was administered 5 ⁇ l per eye for 1 hour for 5 hours.
  • ThE in FIG. 2A shows the epithelial thickness measurement range.
  • Figure 3 is a photograph of the immunohistochemical observation of the degree of apoptosis of the cornea in a dry blowing induced eye dry model using PARP ⁇ Poly (ADP-ribose) polymerase ⁇ .
  • A is a normal control group
  • B is a dry blowing induced negative control group
  • C is a drug control group
  • D is a test group administered the superoxide dismutase fusion protein of the present invention.
  • Each drug was administered 5 ⁇ l per eye for 1 hour for 5 hours.
  • the scale bar in the figure is 80 ⁇ m.
  • Control 4 is a photograph taken with a slit lamp after illuminating a fluorescent light source after 1 ⁇ l of 1% fluorescein in a BTX-A-induced dry eye syndrome model.
  • Control is normal control group
  • Saline is saline added control group
  • BTX is BTX-A added control group
  • SOD is a test group administered superoxide dismutase protein, not fusion protein
  • Tit -SOD "is a test group administered superoxide dismutase fusion protein.
  • Each drug was administered 5 ⁇ l per eye for 1 hour for 5 hours.
  • Restriction enzymes and T4 DNA ligase were purchased from Promega (USA) and Pfu polymerase was purchased from stratagene (USA). Tat oligonucleotides were synthesized in Gibco BRL custom primer (USA). IPTG was purchased from Duchefa (Netherland). pET-15b and BL21 (DE3) plasmids were purchased from Novagen (USA) and Ni-nitrilo-triacetic acid Sepharose superflow was purchased from Qiagen (Germany).
  • Human superoxide dismutase (mixed herein with the same meaning as “superoxide dismutase", “SOD”) cDNA was isolated from human placental cDNA library by polymerase chain reaction method [Kang, JH, Choi, BJ and Kim, S. M. (1997) J. Biochem. Mol. Biol. 30, 60-65]. All other reagents were used as express products.
  • the fusion protein was prepared using human superoxide dismutase, but the scope of the present invention does not only affect the fusion protein using human superoxide dismutase, but it is a yeast-derived, bacterial-derived enzyme. It is also found that the effect of the present invention can be obtained even when using the above.
  • a fusion protein expression vector capable of delivering a target protein into a cell was prepared, and a human super-penetration was performed to easily analyze the ability of the PEP-1 peptide to deliver the protein into the cell. Oxide dismutase was selected.
  • PEP-1-SOD To produce a fusion protein, a pET-PEP expression vector containing a PEP-1 peptide (KETWWE TWWTEW SQP KKKRKV) (SEQ ID NO: 1) was prepared. Two types of oligonucleotides corresponding to the PEP-1 peptide (top chain, 5'-TATGAAAGAAACCTGGTGGGAAACCTGGTGGACCGAATGGTCTCAGCCGAAAAAAAAACGTAAAGTGC-3 '(SEQ ID NO: 15); NdeI - XhoI It was inserted by ligation to pET-15b cut with restriction enzyme.
  • PEP-1 peptide KETWWE TWWTEW SQP KKKRKV
  • oligonucleotides were synthesized based on the cDNA sequence of human superoxide dismutase.
  • Forward primer is 5'-CTCGAGGCGACGAAGGCCGTGTGCGTG-3 '(SEQ ID NO: 17)
  • XhoI Restriction primer and reverse primer is 5'-GGATCCTTATTGGGCGATCCCAATTAC-3 '(SEQ ID NO: 18) BamHI It has a restriction site.
  • PCR Polymerase chain reaction
  • coli BL21 (DE3) transformed with PEP-1-SOD was selected and overexpressed of the recombinant PEP-1-SOD fusion protein by inoculating colonies into 100 ml LB medium and adding IPTG (0.5 mM) into the medium. Induced. Overexpressed PEP-1-SOD fusion protein was confirmed by SDS-PAGE and Western blot analysis.
  • the method was modified to produce SOD-PEP-1 fusion protein and PEP-1-SOD-PEP-1 fusion protein.
  • E. coli BL21 (DE3) cells containing human SOD cDNA prepared in Example 1 in PEP-1-SOD form were placed in LB medium containing ampicillin and cultured at 37 ° C. at 200 rpm.
  • OD 600 0.5 to 1.0
  • IPTG was added to the medium to bring the final concentration to 0.5 and 1 mM, followed by further incubation at 30 ° C for 12 hours.
  • the cultured cells were collected by centrifugation, and then 5ml binding buffer (5mM imidazole, 0.5M NaCl, 20mM Tris-HCl, pH 7.9) was added and pulverized by an ultrasonic grinder.
  • the supernatant was immediately centrifuged Ni 2+ - acrylonitrile triazol setik acid Sepharose Super flow (Ni 2+ -nitrilotriacetic acid sepharose super flow ) load the column and binding buffer of 10 times by volume with 6-fold volume wash buffer (60mM of The fusion protein was washed with imidazole, 0.5M NaCl, 20mM Tris-HCl, pH 7.9) followed by elution buffer (1M imidazole, 0.5M NaCl, 20mM Tris-HCl, pH 7.9). Subsequently, the fractions containing the fusion protein were collected and PD-10 column chromatography was performed to remove salts contained in the fractions.
  • Purified protein concentration was determined by Bradford method using bovine serum albumin as a standard.
  • pET-Tat-SOD expression vector containing superoxide dismutase, transduction site of HIV-1 Tat (Tat49-57) and cDNA for 6 histidines in sequence prepared.
  • a pET-Tat expression vector containing a basic domain of HIV-1 Tat (ie, amino acids 49-57) was prepared.
  • oligonucleotides corresponding to the Tat base domain top strand, 5'-TAGGAAGAAGCGGAGACAGCGACGAAGAC-3 '(SEQ ID NO: 19); bottom strand, 5'-TCGAGTCTTCGTCGCTGTCTCCGCTTCTTCC-3' (SEQ ID NO: 20) )
  • top strand 5'-TAGGAAGAAGCGGAGACAGCGACGAAGAC-3 '(SEQ ID NO: 19); bottom strand, 5'-TCGAGTCTTCGTCGCTGTCTCCGCTTCTTCC-3' (SEQ ID NO: 20)
  • the forward primer has a Xho I restriction site as SEQ ID NO: 17 of Example 1 above
  • the reverse primer has a BamH I restriction site with SEQ ID NO: 18 of Example 1 above.
  • PCR Polymerase chain reaction
  • the reaction mixture was placed in a 50 ⁇ l silicon tube (siliconized reaction tube) and heated at 94 ° C. for 5 minutes.
  • PCR reactions consisted of 30 extensions for 40 seconds at 94 ° C, denaturation for 1 minute at 54 ° C, annealing for 3 minutes at 70 ° C, and final extension for 5 minutes at 20 ° C for 10 minutes at 72 ° C. final extension).
  • the reactants were separated by agarose gel electrophoresis and ligated to TA cloning vectors (Invitrogen, Sandiego, USA).
  • This vector was then transformed into transformant cells and the plasmids were isolated from the transformed bacteria by alkaline lysis method [Sambrook, J., Fritsch, F.E. and Maniatis, T (1989) Molecular cloning, Cold spring harbor laboratory press, Cold spring harbor].
  • TA vectors containing human superoxide dismutase cDNA were digested with Xho I and BamH I and inserted into pET-15b and pET-15b-Tat expression vectors. Expression of the vector is under the control of the T7 promoter and lacO-operator.
  • E. coli BL21 (DE3) transformed with pET-Tat-SOD was selected, then colonies were inoculated in 100 ml LB medium and IPTG (0.5 mM) was added into the medium to induce overexpression.
  • E. coli cells, which induced overexpression of the fusion protein with IPTG, were disrupted by sonication at 4 ° C, and then centrifuged to separate proteins from the supernatant by 15% SDS-polyacrylamide gel electrophoresis. Overexpressed SOD and Tat-SOD were confirmed by SDS-polyacrylamide gel electrophoresis and Western blot analysis.
  • the method was modified to produce SOD-Tat fusion protein and Tat-SOD-Tat fusion protein.
  • the supernatant was immediately loaded by centrifugation into a 2.5 ml Ni 2+ -nitrilotriacetic acid sepharose column and 10-fold volume of binding buffer and 6-volume washing buffer (60 mM imidazole). , 0.5M NaCl, 20mM Tris-HCl, pH 7.9), and then the fusion protein was eluted with elution buffer (1M imidazole, 0.5M NaCl, 20mM Tris-HCl, pH 7.9). Subsequently, the fractions containing the fusion protein were collected, and Sephadex G-15 column chromatography was performed to remove the salts contained in the fractions.
  • the fusion protein contained six histidines at the N-terminus, the fusion protein was purified almost purely (purity> 90%) in a single step of immobilized metal-chelate affinity chromatography. Protein concentrations of the fractions were determined by Bradford method using bovine serum albumin as standard [Bradford, M.A. (1976) Anal. Biochem. 72, 248-254.
  • Surgical epithelial damage of 0.4 mm2 was applied to the median cornea with a surgical knife, and then dry eye was induced by exposure to dry air with a humidity of 25-30% and 2.4 m / sec.
  • Tear secretion changes were tested according to the Schirmer method (cobalt chloride paper; Toyo Roshi Kaisha, Japan).
  • Schirmer test using a phenol red thread is known as the most common method of measuring changes in tear secretion and is the most basic method for evaluating corneal dryness. Fujihara et al. 2001, Invest.Ophthalmol.Vis.Sci. 2001; 42: 96-100, Nakamura et al., Cornea 2004; 23: 390-7).
  • a change in tear secretion amount before and after dry blowing was observed using 1 ⁇ 15 mm cobalt chloride paper.
  • the drug was administered using a dry blowing-induced dry eye model, and the conjunctiva-attached eye was extracted and histopathological observation was performed by PAS (Periodic acid-Schiff) staining.
  • PAS Periodic acid-Schiff
  • the dry eye-induced control group showed damage mainly due to local dropout of the conjunctival epithelium and reduction of the mucous producing cells. There was a significant decrease in the thickness of the conjunctival epithelium, the number and proportion of the mucous producing cells, and the conjunctival epithelium. There was a significant increase in the damage area, respectively.
  • the corneal epithelial cell death was assessed immunohistochemically using PARP ⁇ poly (ADP-ribose) polymerase ⁇ .
  • PARP is a representative apoptosis marker (see Barrett et al., J Histochem Cytochem 2001; 49: 821-32). Increased PARP in corneal epithelium indicates increased corneal epithelial damage due to apoptosis and is caused by dry eye Eye injury is also known to be involved in some degree of cell death (see Yeh et al., Invest.Ophthalmol. Vis. Sci. 2003; 44: 124-9).
  • Dry-secreted portion of the botulinum toxin-A-induced mouse dry eye model was injected with 20 mU of BTX-A into the transconjunctival root in the lacrimal gland and the tear-secreting portion of the lacrimal gland orbital lobe. ) was injected with BTX-A to cause dry eye syndrome.
  • Corneal penetration rate of fluorescent dyes is the most common method of assessing corneal permeability. Increased permeability is known to mean increased corneal damage (see Yokoi & Kinoshita, Cornea 1995; 14: 485-9, Nakamura et. al., Invest.Ophthalmol.Vis.Sci.
  • the corneal permeability was significantly increased compared to the normal group.
  • the test group was divided into a superoxide dismutase protein and a superoxide dismutase fusion protein.
  • the superoxide dismutase fusion protein group significantly decreased the fluorescence transmittance compared to the superoxide dismutase protein group.
  • the main toxicological observations were mortality, clinical symptoms, weight change, autopsy findings, organ weight, histopathological changes, and long-term observations were lung, heart, thymus, kidney, adrenal gland, spleen, testis / ovary, liver, pancreas, brain, 17 sites including the epididymis / uterus, the submandibular lymph nodes, the bladder, the prostate gland, and the dorsal vein.
  • the superoxide dismutase fusion protein showed no death in both low and high dose groups, and the clinical symptoms, weight, organ weight, gross and histological abnormalities due to the drug administration would be very safe. Judging.
  • Table 4 Ingredient Content (mg) chief ingredient Tat-SOD 5 pH regulator Hydrochloric acid Quantity Sodium hydroxide Quantity Tonicity Sodium chloride 700 Potassium chloride 150 Buffer Aminocaproic acid 200 stabilizator Sodium Ethate 10 Preservative Benzalkonium chloride 30 solvent Sterilized Purified Water Quantity Total amount 100 ml
  • the superoxide dismutase fusion proteins according to the present invention can be used as protein therapeutics for ophthalmic diseases.
  • Sequences attached to the present invention are primer sequences, fusion protein sequences associated with protein transport domain sequences and protein transport domains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un agent destiné à traiter les yeux secs, et plus particulièrement une composition pharmaceutique destinée à traiter les yeux secs, contenant, comme principe actif, la protéine hybride de superoxyde dismutase, apte à pénétrer dans le tissu oculaire.
PCT/KR2011/002394 2011-02-15 2011-04-06 Composition pharmaceutique contenant la protéine hybride de superoxyde dismutase, destinée à prévenir ou traiter les maladies des yeux WO2012111878A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0013167 2011-02-15
KR1020110013167A KR101214364B1 (ko) 2011-02-15 2011-02-15 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물

Publications (1)

Publication Number Publication Date
WO2012111878A1 true WO2012111878A1 (fr) 2012-08-23

Family

ID=46672772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002394 WO2012111878A1 (fr) 2011-02-15 2011-04-06 Composition pharmaceutique contenant la protéine hybride de superoxyde dismutase, destinée à prévenir ou traiter les maladies des yeux

Country Status (2)

Country Link
KR (1) KR101214364B1 (fr)
WO (1) WO2012111878A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531246B1 (ko) * 2021-12-23 2023-05-11 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
WO2023128078A1 (fr) * 2021-12-27 2023-07-06 주식회사 제노포커스 Superoxyde dismutase et son utilisation pour la prévention ou le traitement du syndrome de l'œil sec
KR102518033B1 (ko) * 2022-05-16 2023-04-05 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도
WO2023224136A1 (fr) * 2022-05-16 2023-11-23 주식회사 제노포커스 Superoxyde dismutase et ses utilisations pour la prévention ou le traitement de la rétinopathie diabétique ou de l'uvéite

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020010445A (ko) * 2000-07-26 2002-02-04 최수영 세포침투성 티에이티-슈퍼옥사이드 디스뮤테이스융합단백질 및 그 용도
KR20040075236A (ko) * 2003-02-20 2004-08-27 최진희 세포투과성 수송도메인 융합단백질과 그 용도
KR20060109947A (ko) * 2003-11-20 2006-10-23 오쎄라 파마슈티걸즈, 인크. 황반 변성 및 다른 안과 질환의 개선
KR100815278B1 (ko) * 2006-07-25 2008-03-19 주식회사 케이티앤지 눈의 산화적 손상을 예방할 수 있는 건강기능식품 조성물
KR100951606B1 (ko) * 2001-12-14 2010-04-09 알콘 인코포레이티드 안과 질환 및 질병의 치료를 위한 과산화물 디스뮤타제모방체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020010445A (ko) * 2000-07-26 2002-02-04 최수영 세포침투성 티에이티-슈퍼옥사이드 디스뮤테이스융합단백질 및 그 용도
KR100951606B1 (ko) * 2001-12-14 2010-04-09 알콘 인코포레이티드 안과 질환 및 질병의 치료를 위한 과산화물 디스뮤타제모방체
KR20040075236A (ko) * 2003-02-20 2004-08-27 최진희 세포투과성 수송도메인 융합단백질과 그 용도
KR20060109947A (ko) * 2003-11-20 2006-10-23 오쎄라 파마슈티걸즈, 인크. 황반 변성 및 다른 안과 질환의 개선
KR100815278B1 (ko) * 2006-07-25 2008-03-19 주식회사 케이티앤지 눈의 산화적 손상을 예방할 수 있는 건강기능식품 조성물

Also Published As

Publication number Publication date
KR101214364B1 (ko) 2012-12-21
KR20120093541A (ko) 2012-08-23

Similar Documents

Publication Publication Date Title
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
WO2012111877A1 (fr) Composition de gouttes ophtalmiques contenant une protéine hybride pour la protéine de liaison de fk506, destinée à prévenir ou traiter les maladies des yeux
US11759499B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
US10059742B2 (en) Peptides and methods and uses thereof for preventing retinal disorders
US11918577B2 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
US10010586B2 (en) Method of treating intraocular tissue pathologies with nerve growth factor
WO2012111878A1 (fr) Composition pharmaceutique contenant la protéine hybride de superoxyde dismutase, destinée à prévenir ou traiter les maladies des yeux
KR20080031195A (ko) 각결막 질환의 예방 또는 치료제
KR20110020819A (ko) 안구건조증 및/또는 각막/결막 질환 치료용 약학 조성물
KR101906494B1 (ko) 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물
KR20220063190A (ko) 안과 장애의 치료 또는 예방에 사용하기 위한 제제
JP5851692B2 (ja) 網膜神経節ニューロン変性を予防又は治療するためのビコイドファミリーのホメオタンパク質の使用
KR102646717B1 (ko) 세포 침투성 펩타이드와 fkbp12를 포함하는 융합 단백질 및 이의 용도
KR102653532B1 (ko) 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도
CN105017406B (zh) 一类新的具有神经保护功能的多肽
KR20140046781A (ko) 보체인자 ｈ를 포함하는 맥락막 신생혈관 생성 예방 또는 치료용 조성물
CN116966272A (zh) 一种sgp130蛋白在制备治疗角膜炎症及角膜炎适应症产品中的应用
WO2001064242A1 (fr) Medicaments ameliorant la fonction retinienne

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11858607

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11858607

Country of ref document: EP

Kind code of ref document: A1